Amneal Pharmaceuticals (AMRX) Restructuring Costs (2017 - 2026)

Amneal Pharmaceuticals has reported Restructuring Costs for 10 years, with the latest figure at $7.6 million in Q2 2026.

• On a quarterly basis, Restructuring Costs rose 642.19% year-over-year to $7.6 million in Q2 2026; TTM through Jun 2026 was $15.4 million, a 579.91% increase from a year earlier, with the FY2025 full-year figure at $4.2 million, up 78.68% from the prior year.
• Restructuring Costs was $7.6 million for Q2 2026 at Amneal Pharmaceuticals, up from $5.2 million in the prior quarter.
• The five-year high for Restructuring Costs was $7.6 million in Q2 2026, with the low at $82000.0 in Q2 2023.
• Average Restructuring Costs over 5 years is $1.3 million, with a median of $571000.0 recorded in 2025.
• The sharpest annual moves came in 2022 and 2026: Restructuring Costs plunged 98.51% in 2022, then surged 802.45% in 2026.
• Over 5 years, Restructuring Costs stood at $109000.0 in 2022, then increased by 4.59% to $114000.0 in 2023, then surged by 332.46% to $493000.0 in 2024, then surged by 401.01% to $2.5 million in 2025, then soared by 207.69% to $7.6 million in 2026.
• The last three Restructuring Costs figures came in at $7.6 million (Q2 2026), $5.2 million (Q1 2026), and $2.5 million (Q4 2025), per Business Quant data.